• T-cell cytotoxicity specificity and MHC/H-2 restriction shape antiviral immunity across diverse infections, with cross-reactivity patterns shaping immunity. Key results include LCMV target lysis requiring H-2 compatibility [5], H-2K/H-2D-related cytotoxic specificities and cross-reactivity in influenza contexts [4], and virus-infected target lysis by H-2–restricted T cells [10], among others [14][17][11].

• Interferons and mediators regulate antiviral immunity and antibody production in vitro and in circulation, illustrating interferons' dual roles as antiviral agents and immune modulators. Demonstrated IFN–mediated suppression of antibody synthesis [6], circulating migration inhibitory factor and IFN in delayed hypersensitivity [8], interferon purification methods [9], and synthesis/induction reviews [20].

• Viral antigen processing and localization studies reveal EBV early antigens and antigen complexes, with EBV antigens localized in producer vs non‑producer lymphoblastoid lines and distinct early antigen components identified; cross‑virus antibody recognition also appears in HSV contexts [3][16][7].

• Host genetic determinants of antiviral immunity show that the H-2 complex, delayed-type hypersensitivity transfer, and Fv-2 locus govern T cell responses and spleen-focused antiviral dynamics, highlighting genotype-driven modulation of cytotoxic T cell activity and virus-specific immunity [17][5][18][11].